Walter Alexander
Authored Items
SYDNEY—One-year results in meta static melanoma for PV-10 (Rose Bengal, Provectus Pharmaceuticals) confirm positive interim findings found earlier with the first 40 patients. The updated analysis of the full 80-patient cohort was presented by Sanjiv Agarwala, MD, at the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting, held at the 2010 International Melanoma Research Congress. Interim findings had been presented at the annual meeting of the American Society of Clinical Oncology in June. All patients had stage III/IV melanoma.
Read More ›ORLANDO—In newly diagnosed multiple myeloma, the greatest benefits of continuous lenalidomide maintenance after melphalan, prednisone, and lenalidomide induction (MPR-R) are conferred to patients aged between 65 and 75 years. The finding emerged from results of the MM-015 study presented by Antonio Palumbo, MD, University of Torino, Italy. Palumbo’s analysis of the phase 3 study also showed continuous lenalidomide therapy to be superior to regimens of limited duration.
Read More ›SAN ANTONIO—In the phase 2 TAMRAD trial, tamoxifen (TAM) with everolimus (RAD) conferred the greatest clinical benefits over tamoxifen alone among patients with secondary hormone resistance after treatment with an aromatase inhibitor (AI).
Read More ›What important changes in recent years do those treating patients with lymphoma need to keep in focus? Those treating newly diagnosed T-cell lymphomas, according to Owen A. O’Connor, MD, PhD, professor of medicine and pharmacology and chief of the division of hematologic malignancies and medical oncology at the New York University Langone Medical Center Cancer Institute in New York City, need to enroll their patients in clinical trials of combinations of newer agents, and those treating mantle cell lymphomas can consider upfront autologous stem cell transplant (SCT).
Read More ›